- Home
- GLQ vs BDSX Comparison
GLQ vs BDSX Comparison
Compare GLQ & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLQ
- BDSX
- Stock Information
- Founded
- GLQ 2005
- BDSX 2005
- Country
- GLQ United States
- BDSX United States
- Employees
- GLQ N/A
- BDSX N/A
- Industry
- GLQ Finance/Investors Services
- BDSX Precision Instruments
- Sector
- GLQ Finance
- BDSX Health Care
- Exchange
- GLQ Nasdaq
- BDSX Nasdaq
- Market Cap
- GLQ 119.5M
- BDSX 115.4M
- IPO Year
- GLQ N/A
- BDSX 2020
- Fundamental
- Price
- GLQ $6.49
- BDSX $0.37
- Analyst Decision
- GLQ
- BDSX Strong Buy
- Analyst Count
- GLQ 0
- BDSX 4
- Target Price
- GLQ N/A
- BDSX $2.83
- AVG Volume (30 Days)
- GLQ 65.5K
- BDSX 638.4K
- Earning Date
- GLQ 01-01-0001
- BDSX 05-13-2025
- Dividend Yield
- GLQ 11.11%
- BDSX N/A
- EPS Growth
- GLQ N/A
- BDSX N/A
- EPS
- GLQ N/A
- BDSX N/A
- Revenue
- GLQ N/A
- BDSX $71,323,000.00
- Revenue This Year
- GLQ N/A
- BDSX $32.90
- Revenue Next Year
- GLQ N/A
- BDSX $24.65
- P/E Ratio
- GLQ N/A
- BDSX N/A
- Revenue Growth
- GLQ N/A
- BDSX 45.30
- 52 Week Low
- GLQ $5.13
- BDSX $0.45
- 52 Week High
- GLQ $6.54
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- GLQ 62.75
- BDSX 29.45
- Support Level
- GLQ $6.22
- BDSX $0.34
- Resistance Level
- GLQ $6.12
- BDSX $0.58
- Average True Range (ATR)
- GLQ 0.08
- BDSX 0.06
- MACD
- GLQ 0.05
- BDSX -0.01
- Stochastic Oscillator
- GLQ 87.84
- BDSX 12.15
About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.